



CASE STUDY

Entrada Emerges

Company

Entrada is establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. Through its proprietary EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system.

A Different Approach

When Entrada was in its early stages, experimental results began coming in that led the company to conclude it needed to expand its team and access animal research space. Initially, Entrada considered a traditional lease and build to accommodate its emerging needs. However, after evaluating the costs of a buildout, the long-term commitment of a lease, and the amount of time required to access the space, it sought out alternative options.

Entrada joined SmartLabs in 2020, where it quickly launched its research program in customized spaces capable of supporting multiple R&D programs, process development, analytical labs, and access to onsite vivarium space. And with SmartLabs' agile operations and support

“I have been immensely impressed with the level of resourcing and flexibility of SmartLabs’ offering. The cost, time savings and control we have over our science is invaluable and provides a much-needed alternative to building, resourcing and running our own lab operations.”

Nate Dowden

Chief Operating Officer
Entrada Therapeutics



teams, Entrada was able not only to bring previously outsourced workflows in-house, but also allow its research teams to focus their efforts on what they did best: generating data and hitting key milestones.

As its research advanced, Entrada required its space to change and advance with it, adding additional lab workflows and space requirements. At a traditional lab, these changes would have taken months to complete. At SmartLabs, they took just a few weeks. SmartLabs' flexible infrastructure continues to quickly adapt and pivot, allowing Entrada to advance its research continuously and without delay.

A Different Approach Made a Big Difference

Within 18 months of joining SmartLabs, Entrada's team grew more than 4-fold. By enabling Entrada to bring their entire process in-house, SmartLabs helped the company significantly streamline its process and accelerate its development timeline, which helped it close two additional funding rounds for a total of over \$140M, as well as issue an IPO by late 2021.